Clinical Trial

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-07-24; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2024-11-04
Trial Details
NCT Number NCT06520345
Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 520 participants
Start Date 2024-07-26
Primary Completion 2027-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-21